Skip to main content.

Mark J. Hamblin, M.D., FCCP

Mark Hamblin portrait
Associate Professor, Pulmonary, Critical Care and Sleep Medicine

Professional Background

I am an Associate Professor, and the Director of the KU ILD and Rare Lung Disease Program. I care for patients with pulmonary fibrosis, and inflammatory interstitial lung diseases, along with rare parenchymal lung diseases such as sarcoidosis, lymphangioleiomyomatosis (LAM), DIPNECH, and others. I am the principal investigator on multiple research studies focused on pulmonary fibrosis and other rare parenchymal lung diseases.

Education and Training
  • BS, Univ. of Missouri
  • MD, Univ. of Missouri
  • Residency, Internal Medicine, Tulane University Health Sciences Center, New Orleans, LA
  • Post Doctoral Fellowship, Pulmonary & Critical Care, Johns Hopkins, Baltimore, MD
Licensure, Accreditations & Certifications
  • Mark Hamblin, MD, Missouri Board of Healing Arts
  • Mark Hamblin, MD, University of Kansas
Professional Affiliations
  • World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG), WASOG, Member, 2017 - Present
  • Rare Lung Disease Consortium (RLDC), Member, 2015 - Present
  • Lymphangioleiomyomatosis Foundation, Member, 2014 - Present
  • American Thoracic Society, Member, 2009 - Present



I have a primary research focus in interstitial lung disease/pulmonary fibrosis. I serve as the principal investigator for multiple pharmaceutical sponsored clinical trials developing therapeutic agents for patients living with Idiopathic Pulmonary Fibrosis. I also have a scholarly interest in early and accurate detection of interstitial lung disease/pulmonary fibrosis. This includes quality improvement initiatives directed at primary care physicians to enhance detection of patients with pulmonary fibrosis, as well as telemedicine outreach projects to help community pulmonologists with more accurate diagnostic and management strategies. I also collaborate with other pulmonologists nationally to improve our understanding of various interstitial lung diseases.

  • Raghu, Ganesh, Hamblin, Mark. 2022. Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study. Respiratory Research
  • Hamblin, Mark. 2022. Clinical course and management of hypersensitivity pneumonitis. . European Respiratory Review
  • Raghu, Ganesh, Hamblin, Mark. 2021. Randomized Phase 2a and Phase 2b Study of an Anti-αvβ6 IgG1 Monoclonal Antibody (BG00011) in Idiopathic Pulmonary Fibrosis. . American Journal of Respiratory & Critical Care Medicine
  • Jibbe , Neill , Hamblin, Mark. 2021. A Case of Autoimmune Myocarditis Treated with IL-17 Inhibition.